The lectin-like oxidized LDL receptor-1: a new potential molecular target in colorectal cancer

Oncotarget
Michela MurdoccaFederica Sangiuolo

Abstract

The identification of new biomarkers and targets for tailored therapy in human colorectal cancer (CRC) onset and progression is an interesting challenge. CRC tissue produces an excess of ox-LDL, suggesting a close correlation between lipid dysfunction and malignant transformation. Lectin-like oxidized LDL receptor-1 (LOX-1) is involved in several mechanisms closely linked to tumorigenesis. Here we report a tumor specific LOX-1 overexpression in human colon cancers: LOX-1 results strongly increased in the 72% of carcinomas (P<0.001), and strongly overexpressed in 90% of highly aggressive and metastatic tumours (P<0.001), as compared to normal mucosa. Moreover LOX-1 results modulated since the early stage of the disease (adenomas vs normal mucosa; P<0.001) suggesting an involvement in tumor insurgence and progression. The in vitro knockdown of LOX-1 in DLD-1 and HCT-8 colon cancer cells by siRNA and anti-LOX-1 antibody triggers to an impaired proliferation rate and affects the maintenance of cell growth and tumorigenicity. The wound-healing assay reveals an evident impairment in closing the scratch. Lastly knockdown of LOX-1 delineates a specific pattern of volatile compounds characterized by the presence of a butyrate derivative...Continue Reading

References

May 3, 2002·Journal of the American College of Cardiology·Jawahar L Mehta, Dayuan Li
Nov 7, 2002·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·M MorgantiR Giardino
Jan 23, 2003·Proceedings of the National Academy of Sciences of the United States of America·Megumi HonjoTatsuya Sawamura
Feb 8, 2005·The Journal of Biological Chemistry·HaJeung ParkJeffrey C Boyington
Sep 3, 2005·The New England Journal of Medicine·Soko SetoguchiSebastian Schneeweiss
Aug 25, 2007·Arteriosclerosis, Thrombosis, and Vascular Biology·Abhijit DandapatJawahar L Mehta
Sep 27, 2007·JAMA : the Journal of the American Medical Association·Annie On On ChanShiu Kum Lam
Jan 15, 2008·Journal of Molecular and Cellular Cardiology·Silvia BioccaGiuseppe Novelli
Aug 12, 2009·The FEBS Journal·Wei CaoHeather H Shih
Aug 27, 2009·PloS One·Steven A L W VanhoutvinRobert J M Brummer
Oct 8, 2009·Nature Nanotechnology·Gang PengHossam Haick
Dec 18, 2010·Journal of Gastroenterology·Tsutomu YoshidaIsao Okayasu
Feb 23, 2011·Antioxidants & Redox Signaling·Jingjun LuJawahar L Mehta
Sep 21, 2012·Chemical Reviews·Meggie HakimHossam Haick
Jan 7, 2015·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Feb 20, 2015·Journal of Cancer Research and Therapeutics·Chun-Jie LiGuan-Wei Fan
May 8, 2015·Cell Cycle·Silvia BioccaMattia Falconi
Oct 7, 2015·Oncotarget·Agne KrilaviciuteHermann Brenner

❮ Previous
Next ❯

Citations

Feb 2, 2017·International Journal of Molecular Sciences·Barbara RizzacasaFrancesca Amati
Jul 25, 2019·Journal of Biochemical and Molecular Toxicology·Bushra Zeya, Nimai C Chandra
Oct 4, 2019·European Journal of Immunology·Kazuya ToneGordon D Brown
Dec 17, 2016·Cancer Biomarkers : Section a of Disease Markers·Zhao-Yang YangHai Zeng
Apr 12, 2020·International Journal of Clinical Oncology·Chiyo Nakashima-NakasugaHiroaki Nagano
Mar 7, 2020·Frontiers in Immunology·Marion DrouinElise Chiffoleau
Oct 15, 2019·Frontiers in Oncology·Michela MurdoccaFederica Sangiuolo
Oct 29, 2018·Pathology Oncology Research : POR·Mousa Ghazi-KhanloosaniAbbas Pakdel
Feb 6, 2019·Cell Death & Disease·Sabina PucciGiuseppe Novelli
Jun 20, 2018·Cancer Chemotherapy and Pharmacology·Mohammad MahmoudianAhmad Yari Khosroushahi
Jan 7, 2021·Cancer Gene Therapy·M MurdoccaF Sangiuolo
Aug 28, 2021·Cancers·Michela MurdoccaFederica Carla Sangiuolo

❮ Previous
Next ❯

Methods Mentioned

BETA
acetylation
transfection

Software Mentioned

Matlab
GCMS

Related Concepts

Related Feeds

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.